Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

Bo Huang; Lu Tian; Enayet Talukder; Mace Rothenberg; Dae Hyun Kim; Lee-Jen Wei

doi:10.1001/jamaoncol.2018.0275

Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

JAMA Oncol. 2018 Jun 1;4(6):874-876. doi: 10.1001/jamaoncol.2018.0275.

Authors

Bo Huang¹, Lu Tian², Enayet Talukder¹, Mace Rothenberg³, Dae Hyun Kim⁴, Lee-Jen Wei⁵

Affiliations

¹ Pfizer Inc, Groton, Connecticut.
² Stanford Medical School, Stanford University, Stanford, California.
³ Pfizer Inc, New York, New York.
⁴ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Department of Biostatistics, Harvard University, Boston, Massachusetts.

Abstract

This study evaluates the duration of response for crizotinib vs chemotherapy for patients with ALK-positive lung cancer using data from the PROFILE-1014 randomized clinical trial.

MeSH terms

Anaplastic Lymphoma Kinase / analysis
Anaplastic Lymphoma Kinase / antagonists & inhibitors
Antineoplastic Agents / therapeutic use
Clinical Trials, Phase III as Topic / statistics & numerical data
Crizotinib / therapeutic use
Humans
Kaplan-Meier Estimate*
Lung Neoplasms / drug therapy
Lung Neoplasms / enzymology
Lung Neoplasms / mortality
Molecular Targeted Therapy
Multicenter Studies as Topic / statistics & numerical data
Neoplasm Proteins / analysis
Neoplasm Proteins / antagonists & inhibitors
Neoplasms / therapy*
Progression-Free Survival*
Protein Kinase Inhibitors / therapeutic use
Randomized Controlled Trials as Topic / statistics & numerical data
Time Factors
Treatment Outcome*

Substances

Antineoplastic Agents
Neoplasm Proteins
Protein Kinase Inhibitors
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase